Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172955 | 1.00 | HRH3 (0.56) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL439509 | 0.98 | HRH3 (0.52) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL441058 | 0.93 | HRH3 (0.61) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL441042 | 0.93 | HRH3 (0.46) | HRH3MAPTSMN1; SMN2LSSGBA1 | |
| SCHEMBL10778023 | 0.91 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7866253 | 0.91 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL6246899 | 0.91 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL439740 | 0.91 | HRH3 (0.56) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL21016238 | 0.88 | HRH3 (0.61) | HRH3MAPTLSSMEN1KMT2A | |
| SCHEMBL38662815 | 0.88 | HRH3 (0.61) | HRH3MAPTLSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202848-B2 | Phosphoramidite activator | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| EP-4393921-A1 | NALIDINONE COMPOUND AS FGFR4 INHIBITOR AND USE THEREOF | Wenzhou Medical University (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| CN-114555617-B | Phosphoramidite activators | 富士胶片和光纯药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-4047004-B1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20240026051-A1 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | MIRUS BIO LLC | 2024-01-25 | — | — | US | disclosed |
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | S＆K THERAPEUTICS (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | HRH3 1587/4885MAPT 4564/4885CYP1A2 227/4885 |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | ITPA, INPP5D, INPP5B | HRH3 2265/4885MAPT 2951/4885CYP1A2 4315/4885 |
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | TLR9, TLR8, TLR3 | HRH3 1484/4885MAPT 3661/4885CYP1A2 4877/4885 |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | HRH3 245/4885MAPT 4305/4885CYP1A2 57/4885 |
| US-12202848-B2 | Phosphoramidite activator | ITPA, INPP5D, INPP5B | HRH3 2265/4885MAPT 2951/4885CYP1A2 4315/4885 |
| US-20240026051-A1 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | SLC7A1, PARN, PARG | HRH3 49/4885MAPT 3754/4885CYP1A2 4865/4885 |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | HRH3 2295/4885MAPT 264/4885CYP1A2 1118/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | HRH3 3657/4885MAPT 371/4885CYP1A2 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.